Market Overview
Global Automated Compounding Devices Market will grow from USD 2.35 billion in 2024 to USD 6.19 billion by 2033, at a CAGR of 11.4% during the forecast period 2025-2033.
Automated Compounding Systems (ACS), also known as Pharmacy Automation Systems or Automated Compounding Devices (ACD), are innovative machines used in healthcare settings, primarily in pharmacies and hospitals, to manufacture specialised drugs and intravenous (IV) solutions. The manufacturing of sterile and non-sterile drugs has become more accurate, safe, and efficient thanks to these equipment, which have revolutionised the industry.
In hospitals and healthcare facilities, ACDs are often used to manufacture IV medicines and solutions. They carefully weigh out and combine the necessary medications, guaranteeing the proper dosage and lowering the chance of contamination. TPN solutions, which are individualised concoctions of nutrients and drugs for patients who are unable to receive nutrition through oral or enteral methods, are made using ACDs. The ACDs make sure that these intricate formulas are accurate and sterile.
Market Summary
| Metrics | Details |
| CAGR | 11.4% |
| Size Available for Years | 2024-2033 |
| Forecast Period | 2025-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Product Type, Technology, Component, Mode of Operation, End-User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics
Technological advancements in Automated Compounding Devices
For many different factors, including the goal to improve patient safety, streamline pharmacy operations, and satisfy changing healthcare needs, Automated Compounding Devices (ACDs) are always improving and developing technological improvements. For instance, in December 2022, ExactaMix Pro Automated Compounder will be made available to consumers in the United States in early 2023, according to a statement from Baxter International Inc. In comparison to ExactaMix, ExactaMix Pro offers improved security, more user-friendly and useful features, and higher processing power.
Moreover, in March 2022, according to Omnicell, Inc., the launch of IVX Station. This ground-breaking approach aims to scale the advantages of utilising IV robotic technology and make it available to the general public. New technology and improvements to current products are included in Omnicell's Winter 2022 Release, which is anticipated to benefit customers.
Additionally, by precisely preparing the necessary amount and avoiding the need to discard extra medications, ACDs can help reduce medication waste. In the medical field, shortages of ready-to-use, commercially available drugs are not unusual. In cases where commercially accessible items are not available, ACDs enable healthcare facilities to produce drugs on-site. ACDs can need a substantial initial investment, but over time, by lowering drug errors, reducing waste, and improving pharmacy operations, they can result in cost savings.
Market Dynamics: Restraint
While automated compounding devices offer several advantages for healthcare settings, there are also a number of barriers and difficulties in implementing them. For instance, ACDs may compound drug shortages in some situations because they may rely on pre-filled drug vials or cartridges; when there is a shortage of those supplies, it can affect the compounding process and healthcare professionals may be reluctant to adopt new technology or alter long-standing compounding practises.
In addition to the initial investment, ACDs require ongoing maintenance, calibration, and regular servicing, which can add to the total cost of ownership. Resistances like those mentioned above may hinder the adoption of ACDs.
Market Segment Analysis
The global automated compounding devices market is segmented based on product type, technology, component, mode of operation, end-user and region.
The Intravenous (IV) compounding systems segment from the product type segment accounted for approximately 39.7% of automated compounding devices share
Intravenous (IV) compounding systems are essential to healthcare for a number of reasons, including the critical role they provide in maintaining patient safety, enhancing drug delivery, and strengthening the overall standard of care. In healthcare, patient safety is of highest priority. By streamlining the compounding procedure, these devices cut down on the time and labour needed to create IV drugs. The companies' strategies aid in accelerating the segment's growth.
For instance, on October 08, 2021, in order to increase production, Satasairaala Hospital Pharmacy acquired the IV ICON Twins compounding system from NewIcon. The hospital pharmacy now uses a semi-automatic procedure to make antibiotics: a pump administers the solvent, but the remaining compounding steps are done by hand. Each year, this semi-automated process administers around 65,000 doses of medication. Thus, those mentioned factors boost segment expansion.
Market Geographical Share
The widespread acceptance and use of ACDIs in the North American region
The North America will continue its dominance due to the presence of the major pharmaceutical industries across the region. Moreover, the safety of patients receives top priority in the healthcare system in the United States. In keeping with the healthcare sector's dedication to maintaining patient well-being, ACDs are considered as a crucial instrument in lowering the risk of medication errors, contamination, and adverse events related to the preparation of IV medications.
The United States has a history of embracing medical technology early on. The widespread acceptance and use of ACDs in healthcare settings can be attributed to this culture of welcoming novel ideas. The United States is renowned for its contributions to healthcare technology. Continuous research and development have improved automated compounding machines, making them more dependable, user-friendly, and adaptable to varied healthcare settings. Thus, above factors boost the region growth.
COVID-19 Impact Analysis
Positive effects of the COVID-19 epidemic have been noticed in consumer demand for Automated Compounding Devices (ACDs). Sterile compounding was more important than ever because of the rise in COVID-19 cases, especially for drugs and IV solutions used in critical care. ACDs, which are renowned for their capacity to guarantee sterility and precision, were essential in satisfying this requirement.
Due to mistakes in the compounding of medications could have catastrophic repercussions, the pandemic highlighted the significance of pharmaceutical safety and precision. ACDs become even more useful in lowering medication errors thanks to their accurate measurements and safety features. To boost their capacity and capabilities during the epidemic, some healthcare systems and facilities received more funds and resources. This prompted investments in ACDs to increase the capacity and efficiency of pharmacies.
Competitive Landscape
The major global players in the market include Grifols, S.A, Baxter International Inc, COMECER S.p.A., ARxIUM, ICU Medical, Inc, Omnicell, Inc, EQUASHIELD, B. Braun Medical Inc., BECTON, DICKINSON AND COMPANY, SMARTCOMPOUNDERS B.V. and among others.
Key Developments
- In December 2022, the APEX Compounding System and its exclusive TPN Manager Clinical Decision Support Order Entry Software will be presented at the ASHP, according to B. Braun Medical Inc. (B. Braun). The APEX Compounding System was created expressly to fulfil the urgent needs of chemists and patients with critical conditions of all ages, from newborns to adults.
Why Purchase the Report?
- To visualize the global automated compounding devices market segmentation based on product type, technology, component, mode of operation, end-user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of automated compounding devices market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global automated compounding devices market report would provide approximately 77 tables, 79 figures and 189 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
